| Name | Cintirorgon |
| Description | Cintirorgon (LYC-55716) is a selective, oral agonist of RORγ, modulating gene expression in RORγ-expressing T lymphocyte immune cells. |
| In vitro | Upon oral administration of Cintirorgon, this agent selectively binds to the nuclear receptor transcription factor RORγ, forming a receptor complex that translocates to the nucleus, and binds to ROR response elements (ROREs), enhancing the function, proliferation and survival of type 17 T cells, including Th17 (helper T cells) and Tc17 (cytotoxic T cells). RORγ, the nuclear receptor transcription factor that is involved in Th17/Tc17 differentiation, plays a key role in immune activation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 110 mg/mL (182.26 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (5.47 mM), Sonication is recommended.
|
| Keywords | RORγ | ROR | RAR-related orphan receptor | LYC55716 | LYC 55716 | Inhibitor | inhibit | Cintirorgon |
| Inhibitors Related | S18-000003 | GSK2981278 | GSK805 | MRL-871 | Nobiletin | XY101 | AZD-0284 | Melatonin | SR2211 | SR 1903 | Cholesterol | ML 209 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |